新辅助化疗对骨肉瘤多药耐药相关蛋白表达的影响分析

黄铮　易伟宏

[摘要] 目的 探究将不同新辅助化疗方案应用于治疗多药耐药相关蛋白在骨肉瘤组织表达中存在的影响。方法 采用RP-PCR技術以及免疫组化技术，方便选取该院2015年9月—2018年6月间收入的50例骨肉瘤患者进行检验探究，根据患者的不同化疗类型将其分为MMIA方案与DIA方案进行化疗，分别命名为MMIA组和DIA组，每组中均录入25例患者。应用不同新辅助化疗方案实施前后多药耐药相关蛋白在mRNA以及蛋白水平中造成的变化状况分析其影响。 结果 在同一新辅助化疗方案的实施前后，以及不同新辅助化疗方案的实施期间，肿瘤组织的多药耐药蛋白的mRNA以及蛋白表达差异无统计学意义（t=0.565 2，P=0.574 5）。并且在实施新辅助化疗方案后，不同化疗方案患者的肿瘤组织中MRP蛋白表达状况存在差异，MMIA化疗组患者化疗前的MRP阳性率记录为84.00%，而化疗后的阳性率记录为88.00%;而DIA组患者化疗前MRP的阳性率记录为84.00%，化疗后阳性率仍然为84.00%。组间差异经对比分析后，差异无统计学意义，同时化疗前后同组患者的表达状况差异无统计学意义（χ2=0.664 5，P=0.414 9）。 结论 不同新辅助化疗方案在应用于骨肉瘤多药耐药蛋白的治疗中，对其蛋白表达的影响较为有限，其主要耐药性与患者个体状况以及肿瘤本身特性有较为密切的关系，对患者进行多药耐药蛋白表达检测，有助于根据患者的具体状况进行相应的治疗，这样才能保证患者的治疗效果，以达到治疗目的。

[关键词] 新辅助化疗;骨肉瘤;多药耐药;相关蛋白;影响分析

[中图分类号] R738.1          [文献标识码] A          [文章编号] 1674-0742（2019）07（a）-0063-04

Analysis of the Effect of Neoadjuvant Chemotherapy on the Expression of Multidrug Resistance-associated Protein in Osteosarcoma

HUANG Zheng， YI Wei-hong

Department of Spinal Surgery， Nanshan District People's Hospital， Shenzhen， Guangdong Province， 518000 China

[Abstract] Objective To investigate the effects of different neoadjuvant chemotherapy regimens on the expression of multidrug resistance-associated proteins in osteosarcoma tissues. Methods RP-PCR and immunohistochemical techniques were used to investigate 50 cases of osteosarcoma patients from September 2015 to June 2018 in our hospital. According to the different types of chemotherapy， patients were convenient selected and divided into MMIA programs and DIA programs. Chemotherapy was performed in the DIA protocol and was named as MMIA and DIA group， with 25 patients enrolled in each group. The effects of multidrug resistance-associated proteins on mRNA and protein levels before and after the implementation of different neoadjuvant chemotherapy regimens were analyzed. Results There was no statistically significant difference in the mRNA and protein expression of multidrug resistance protein in tumor tissues before and after the implementation of the same neoadjuvant chemotherapy regimen and during the implementation of different neoadjuvant chemotherapy regimens（t=0.565 2， P=0.574 5）. And after the implementation of the neoadjuvant chemotherapy regimen， the expression of MRP protein in the tumor tissues of patients with different chemotherapy regimens was different. The positive rate of MRP before chemotherapy in the MMIA chemotherapy group was recorded as 84.00%， and the positive rate after chemotherapy was recorded as 88.00%; The positive rate of MRP before chemotherapy in the DIA group was 84.00%， and the positive rate after chemotherapy was still 84.00%. After the comparison between the groups， there was no statistical difference， and there was no statistically significant difference in the expression of the same group before and after chemotherapy（χ2=0.664 5，P=0.414 9）. Conclusion Different neoadjuvant chemotherapy regimens have limited effects on the expression of multidrug resistance protein in osteosarcoma， and their main drug resistance and individual patient status and tumor characteristics had a close relationship between the detection of multidrug resistance protein expression in patients， and it is helpful to carry out corresponding treatment according to the specific conditions of patients， so as to ensure the therapeutic effect of patients to achieve therapeutic purposes.